CA3117559C - Hydrogen sulfate salt of a bcl-2 inhibitor, related crystalline form,method for preparing the same and pharmaceutical compositions containing the same - Google Patents

Hydrogen sulfate salt of a bcl-2 inhibitor, related crystalline form,method for preparing the same and pharmaceutical compositions containing the same Download PDF

Info

Publication number
CA3117559C
CA3117559C CA3117559A CA3117559A CA3117559C CA 3117559 C CA3117559 C CA 3117559C CA 3117559 A CA3117559 A CA 3117559A CA 3117559 A CA3117559 A CA 3117559A CA 3117559 C CA3117559 C CA 3117559C
Authority
CA
Canada
Prior art keywords
ppm
compound
crystalline form
hydrogen sulfate
sulfate salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3117559A
Other languages
English (en)
French (fr)
Other versions
CA3117559A1 (en
Inventor
Michael Lynch
Frederic Villard
Patrick Mouchet
Pascal TAULELLE
Ludovic MASSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Vernalis R&D Ltd
Original Assignee
Laboratoires Servier SAS
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS, Vernalis R&D Ltd filed Critical Laboratoires Servier SAS
Publication of CA3117559A1 publication Critical patent/CA3117559A1/en
Application granted granted Critical
Publication of CA3117559C publication Critical patent/CA3117559C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3117559A 2018-10-31 2019-10-30 Hydrogen sulfate salt of a bcl-2 inhibitor, related crystalline form,method for preparing the same and pharmaceutical compositions containing the same Active CA3117559C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306430 2018-10-31
EP18306430.2 2018-10-31
PCT/EP2019/079621 WO2020089281A1 (en) 2018-10-31 2019-10-30 Novel salt of a bcl-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same

Publications (2)

Publication Number Publication Date
CA3117559A1 CA3117559A1 (en) 2020-05-07
CA3117559C true CA3117559C (en) 2023-09-26

Family

ID=64270773

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3117559A Active CA3117559C (en) 2018-10-31 2019-10-30 Hydrogen sulfate salt of a bcl-2 inhibitor, related crystalline form,method for preparing the same and pharmaceutical compositions containing the same

Country Status (37)

Country Link
US (1) US20210355108A1 (lt)
EP (1) EP3873894B1 (lt)
JP (1) JP2022506137A (lt)
KR (1) KR20210092750A (lt)
CN (1) CN112969693A (lt)
AR (1) AR116921A1 (lt)
AU (1) AU2019370926A1 (lt)
BR (1) BR112021007194A2 (lt)
CA (1) CA3117559C (lt)
CL (1) CL2021000947A1 (lt)
CO (1) CO2021005077A2 (lt)
CR (1) CR20210211A (lt)
CY (1) CY1126057T1 (lt)
DK (1) DK3873894T3 (lt)
DO (1) DOP2021000074A (lt)
EA (1) EA202191143A1 (lt)
ES (1) ES2943511T3 (lt)
FI (1) FI3873894T3 (lt)
GE (1) GEP20237494B (lt)
HR (1) HRP20230563T1 (lt)
HU (1) HUE062000T2 (lt)
IL (1) IL282565A (lt)
JO (1) JOP20210072A1 (lt)
LT (1) LT3873894T (lt)
MA (1) MA54063B1 (lt)
MX (1) MX2021004934A (lt)
NI (1) NI202100025A (lt)
PE (1) PE20211503A1 (lt)
PH (1) PH12021550790A1 (lt)
PL (1) PL3873894T3 (lt)
PT (1) PT3873894T (lt)
RS (1) RS64236B1 (lt)
SG (1) SG11202103594XA (lt)
SI (1) SI3873894T1 (lt)
TW (1) TWI791916B (lt)
WO (1) WO2020089281A1 (lt)
ZA (1) ZA202102783B (lt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537290A (ja) 2020-07-31 2023-08-31 レ ラボラトワール セルヴィエ 癌を処置するためのＢｃｌ－２阻害薬と低メチル化剤との組合せ、その使用及び医薬組成物
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
CN116997544A (zh) 2021-03-24 2023-11-03 法国施维雅药厂 用于合成5-{5-氯-2-[(3s)-3-[(吗啉-4-基)甲基]-3,4-二氢异喹啉-2(1h)-羰基]苯基}-1,2-二甲基-1h-吡咯-3-甲酸衍生物的新方法及其在生产药物化合物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
US7432398B2 (en) * 2005-01-06 2008-10-07 Cj Corporation Inorganic acid salts of sibutramine
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
CN101962387B (zh) * 2010-09-13 2013-01-30 成都雅途生物技术有限公司 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法
CN103664753B (zh) * 2012-09-04 2017-04-26 上海迪赛诺化学制药有限公司 制备阿扎那韦硫酸氢盐a型结晶的方法
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2017013219A (es) * 2015-04-15 2018-02-15 Beigene Ltd Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos.

Also Published As

Publication number Publication date
MA54063A (fr) 2021-09-08
US20210355108A1 (en) 2021-11-18
DOP2021000074A (es) 2021-07-22
MX2021004934A (es) 2021-06-08
TW202033517A (zh) 2020-09-16
JP2022506137A (ja) 2022-01-17
CR20210211A (es) 2021-05-25
GEP20237494B (en) 2023-04-10
NI202100025A (es) 2021-08-24
HUE062000T2 (hu) 2023-09-28
MA54063B1 (fr) 2023-06-28
PT3873894T (pt) 2023-04-28
FI3873894T3 (fi) 2023-06-07
CL2021000947A1 (es) 2021-11-19
CA3117559A1 (en) 2020-05-07
ZA202102783B (en) 2022-10-26
RS64236B1 (sr) 2023-06-30
AR116921A1 (es) 2021-06-30
SI3873894T1 (sl) 2023-08-31
CO2021005077A2 (es) 2021-09-20
IL282565A (en) 2021-06-30
LT3873894T (lt) 2023-06-26
PH12021550790A1 (en) 2021-10-25
DK3873894T3 (da) 2023-06-06
EA202191143A1 (ru) 2021-09-10
ES2943511T3 (es) 2023-06-13
EP3873894B1 (en) 2023-03-22
KR20210092750A (ko) 2021-07-26
EP3873894A1 (en) 2021-09-08
HRP20230563T1 (hr) 2023-08-18
CN112969693A (zh) 2021-06-15
AU2019370926A1 (en) 2021-05-20
WO2020089281A1 (en) 2020-05-07
BR112021007194A2 (pt) 2021-07-20
PE20211503A1 (es) 2021-08-11
TWI791916B (zh) 2023-02-11
PL3873894T3 (pl) 2023-07-31
CY1126057T1 (el) 2023-11-15
JOP20210072A1 (ar) 2023-01-30
SG11202103594XA (en) 2021-05-28

Similar Documents

Publication Publication Date Title
CA3117559C (en) Hydrogen sulfate salt of a bcl-2 inhibitor, related crystalline form,method for preparing the same and pharmaceutical compositions containing the same
AU2018202881B2 (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
CN114728899B (zh) 新型三苯基化合物盐
CA2985033C (en) Crystalline form ii of 3-ethyl-4-{3-isopropyl-4-(4-(1-methyl-1h-pyrazol-4-yl)-1h-imidazol-1-yl)-1h­pyrazol0[3,4-b]pyridin-1-yl}benzamide
WO2018117267A1 (ja) 置換ピペリジン化合物の塩
JP2018516946A (ja) ヒストン脱アセチル化阻害剤の結晶形態
EP3891156B1 (en) New crystalline forms of a thienopyrimidine as mcl-1 inhibitor
OA20227A (en) Novel salt of A BCL-2 inhibitor, related crystalline form, method for preparing the same and pharmaceutical compositions containing the same.
EP3189040B1 (en) Novel salts of 3-[(dimethylamino)methyl]-n-{2-[4-(hydroxycarbamoyl) phenoxy]ethyl}-1-benzofuran-2-carboxamide, related crystalline forms, method for preparing the same and pharmaceutical compositions containing the same
EA043392B1 (ru) Новая соль ингибитора bcl-2, соответствующая кристаллическая форма, способ их получения и фармацевтические композиции, которые их содержат
EP4177257A1 (en) Succinate of octahydrothienoquinoline compound, and crystals thereof
CN109422723B (zh) 一种肠2b型磷酸钠协同转运蛋白抑制剂的晶型及其制备方法
KR102026337B1 (ko) 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
WO2019134970A1 (en) Novel salts of a bcl-2 inhibitor,related crystalline forms,method for preparing the same and pharmaceutical compositions containing the same
EA044230B1 (ru) Новые кристаллические формы mcl-1 ингибитора, способ их получения и содержащие их фармацевтические композиции
EP3351542A1 (en) New crystal of piperazine compound
NZ712380B2 (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210423

EEER Examination request

Effective date: 20210423

EEER Examination request

Effective date: 20210423

EEER Examination request

Effective date: 20210423

EEER Examination request

Effective date: 20210423

EEER Examination request

Effective date: 20210423

EEER Examination request

Effective date: 20210423

EEER Examination request

Effective date: 20210423

EEER Examination request

Effective date: 20210423

EEER Examination request

Effective date: 20210423